Projects

Ing. Július Brtko, DrSc.

International

Finished
  • Investigation of selected triorganotin compounds potentially acting as nuclear retinoid X receptor ligands in breast cancer derived cell lines by in silico and in vitro approaches
    Program: Bilateral - other
    Duration: 1. 9. 2024 – 31. 8. 2025
  • In silico and in vitro investigation of novel nuclear retinoid X receptor (RXR) ligands as potential anti-tumour agents.
    Program: Other
    Duration: 1. 5. 2020 – 30. 4. 2023
  • Monitoring of effects of natural and synthetic ligands of nuclear retinoid receptors on key proteins involved in epithelial-mesenchymal transition in human breast cancer cells by the mass spectrometry
    Program: Inter-academic agreement
    Duration: 1. 1. 2018 – 31. 12. 2021
  • Antitumour effect of trialkyl- and triaryltin compounds, biologically active ligands of nuclear retinoid X receptors in human breast cancer cell lines
    Program: Inter-academic agreement
    Duration: 1. 1. 2015 – 31. 12. 2017
  • Chemical contaminants in the food chain
    Program: FP6
    Duration: 1. 1. 2004 – 31. 1. 2010

National

Current
  • Biologically relevant mixtures of endocrine disruptors: effects on in vitro models of ovarian intrafollicular processes and ovarian cancer cell lines
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
  • Investigation of new molecular regulatory mechanisms of selected biologically active 4H-pyran-4-ones in relation to their prospective applicability in human oncology
    Program: VEGA
    Duration: 1. 1. 2024 – 31. 12. 2026
Finished
  • Molecular mechanisms of trialkyl-/triaryltin isothiocyanates\' and carboxylates\' antitumour properties - novel ligands of nuclear retinoid X receptors in rat mammary gland carcinomas and human tumour cell lines
    Program: SRDA
    Duration: 1. 7. 2021 – 30. 6. 2025
  • Multidrug resistance of leukemia cells - Phenotype caused by interference of multimodal molecular reasons
    Program: SRDA
    Duration: 1. 7. 2020 – 30. 5. 2024
  • Molecular regulatory mechanisms and therapeutic potential of retinoid X receptor activation by triorganotin compounds in relation to breast cancer treatment
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2023
  • The safety of use of analogs of the endocrine disruptor Bisphenol A: evaluation of effects on in vitro models of ovarian intrafollicular processes and and ovarian cancer cell lines
    Program: VEGA
    Duration: 1. 1. 2018 – 31. 12. 2020
  • Novel synergistic antitumour properties ofnuclear retinoid X receptor (RXR) agonists as a consequence of the conditional RXR-RAR heterodimer formation in human breast cancer cells
    Program: SRDA
    Duration: 1. 7. 2016 – 31. 12. 2020
  • Potential risk of metal and metal oxide nanoparticles used for biomedical applications: focus on reproductive and immune systems and brain
    Program: SRDA
    Duration: 1. 7. 2016 – 31. 12. 2020
  • Novel additive antitumour effects of nuclear retinoid X receptor (RXR) ligands of natural and synthetic character in human breast and renal carcinoma cells
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2019
  • Possible dual function of P-glycoprotein in leukemia cells: efflux pump and regulatory protein
    Program: SRDA
    Duration: 1. 7. 2015 – 30. 10. 2018
  • Antitumour versus disruption effects of biologically active triaryl-/trialkyl-organometal ligands of retinoid X receptors in tissue cultures of tumour cells
    Program: VEGA
    Duration: 1. 1. 2014 – 31. 12. 2016
  • Antitumour effect of biologically active ligands of nuclear retinoid X receptor heterodimers in tissue carcinoma cell lines
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Centre of Excellence for the study of metabolic aspects of development, diagnostics and treatment of malignancies
    Program:
    Duration: 4. 8. 2011 – 30. 6. 2015
  • -
    Program:
    Duration: 1. 6. 2011 – 31. 12. 2014
  • Center of excellence for the study of metabolic aspects of development, diagnostics and treatment of cancer diseases
    Program:
    Duration: 1. 7. 2011 – 31. 12. 2014
  • Changes in the cell metabolism developed by overexpression of the drug transporter – P-glycoprotein in leukemic cells.
    Program: SRDA
    Duration: 1. 7. 2011 – 31. 12. 2014
  • Application of proteomic techniques for monitoring of biologically active retinoid receptors ligands effects explitable for therapy of breast cancer
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2013
  • Consequences of transactivation processes mediated by rexinoids inducible transcription factors in rat mammary gland carcinoma
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Molecular mechanisms of retinoic acids action in relation to thyroid csrcinoms, breast and renal cancer therapy
    Program: SRDA
    Duration: 1. 2. 2008 – 31. 12. 2010
  • Chemical contaminants in the food chain
    Program:
    Duration: 1. 1. 2004 – 31. 1. 2010
  • Character function and role of transcription factors inducible by bilogicaly active hydrophobic molecules in rat mammary gland
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
Employees